Prospect: information for the user
Ziprasidone Viatris 80 mg hard capsules EFG
Read this prospect carefully before starting to take this medicine, because it contains important information for you.
-Keep this prospect, as you may need to read it again.
-If you have any questions, consult your doctor or pharmacist.
-This medicine has been prescribed only for you, and you should not give it to other peopleeven if they present the same symptoms of illness as you, as it may harm them.
-If you experience any adverse effect, consult your doctor or pharmacist,even if it is an adverse effect that does not appear in this prospect. See section 4.
1.What is Ziprasidone Viatris and for what it is used
2.What you need to know before starting to takeZiprasidone Viatris
3.How to take Ziprasidone Viatris
4.Possible adverse effects
5.Storage of Ziprasidone Viatris
6.Contents of the package and additional information
Ziprasidona Viatris belongs to a group of medicines called antipsychotics.
Ziprasidona is indicated for the treatment of schizophrenia in adults, a mental disorder characterized by the following symptoms:hearing, seeing or feeling things that do not exist, believing in something that is not real, having unusual suspicions, being absent and having difficulty establishing social relationships, nervousness, depression or anxiety.
Ziprasidona is also used for the treatment of episodes of moderate intensity mania or mixed episodes in adult bipolar disorder and in children and adolescents aged 10-17 years, which is a mental disorder characterized by alternating phases of euphoric mood (mania) and depressed mood.During mania episodes, the most characteristic symptoms are: euphoric behavior, exaggerated self-esteem, increased energy, decreased need for sleep, lack of concentration or hyperactivity and repeated high-risk behaviors.
Do not take Ziprasidona Viatris
Also see the section “Other medications and Ziprasidona Viatris” below.
Warnings and precautions
Consult your doctor or pharmacistbeforestarting to take Ziprasidona Viatris:
Inform your doctor if you are taking Ziprasidona Viatrisbefore they perform a blood test (blood, urine, liver function, heart rate, etc.), as it may alter the test results.
Children and adolescents
The safety and efficacy of ziprasidona in the treatment of schizophrenia in children and adolescents have not been established.
Seek medical attention immediately if you experience any of the following symptoms:
Other medications and Ziprasidona Viatris
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Do not take Ziprasidona Viatris
If you are taking medications for heart rhythm or medications that may alter heart rhythm, such as:
Inform your doctor or pharmacist if you are taking or have taken recently medications for the treatment of:
Also see the section "Do not take Ziprasidona Viatris" above.
Ziprasidona Viatris with food, drink, and alcohol
Ziprasidona capsules MUST BE TAKEN WITH A MAIN MEAL.
You should not drink alcohol during treatment with ziprasidona, as it may increase the risk of adverse effects.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor before using this medication.
Pregnancy
Do not take ziprasidona during pregnancy, unless your doctor tells you to, as there is a risk that this medication may harm the fetus. If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
The following symptoms may occur in newborns of mothers who have used ziprasidona in the last trimester (last three months of pregnancy): tremors, stiffness, and/or muscle weakness, drowsiness, agitation, breathing difficulties, and feeding problems. If your baby experiences any of these symptoms, you may need to contact your doctor.
Breastfeeding
You should not breastfeed while taking ziprasidona, as small amounts of the medication may pass into breast milk. If you plan to breastfeed your baby, consult your doctor before taking this medication.
Contraception
If you can become pregnant, you should use an appropriate contraceptive method while taking this medication.
Driving and operating machinery
Treatment with ziprasidona may cause drowsiness. If you experience this symptom, you should not drive or operate machinery until the drowsiness has disappeared.
Ziprasidona Viatris contains lactose.
If your doctor has told you that you have a certain sugar intolerance, contact him before taking ziprasidona.
Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
The capsules must be swallowed whole, without chewing, and must be taken with food. It is essential not to chew the capsules, as this could alter the absorption of the medication in the intestine.
Ziprasidone must be taken twice a day, one capsule in the morning during a complete breakfast and another at night during dinner (see blister pack). This medication should be taken at the same time every day.
Adults
The recommended dose is 40-80 mg twice a day during meals.
In long-term treatments, your doctor may adjust the dose. Do not exceed the maximum dose of 160 mg per day.
Use in children and adolescents with bipolar mania
The initial recommended dose is 20 mg to be taken with a meal; subsequently, your doctor will indicate which are the optimal doses for you. Do not exceed the maximum dose of 80 mg per day in children weighing 45 kg or less, or 160 mg per day in children weighing more than 45 kg.
The safety and efficacy of ziprasidone in the treatment of schizophrenia in children and adolescents have not been established.
Older adults (65 years or older)
If you are an older adult, your doctor will decide on the suitable dose for you. Doses in patients over 65 years old are sometimes lower than those used in younger people. Your doctor will indicate which dose is appropriate for you.
Patients with liver problems
If you have liver problems, you may need to take a lower dose of ziprasidone capsules. Your doctor will determine the suitable dose for you.
If you take more Ziprasidone Viatris than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service (phone 91 562 04 20), indicating the medication and the amount ingested. Bring the ziprasidone box with you.
If you have taken too many ziprasidone capsules, you may experience drowsiness, tremors, seizures, and involuntary movements of the head and neck.
If you forgot to take Ziprasidone Viatris
It is essential to take ziprasidone regularly every day at the same time. If you forget to take a dose, take it as soon as you remember, unless it is already time for the next dose. In that case, take the next dose. Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Ziprasidone Viatris
Your doctor will indicate for how long you should take ziprasidone. Do not stop taking ziprasidone unless your doctor tells you to.
It is essential to continue taking the medication, even if you feel better. If you interrupt treatment too soon, symptoms may reappear.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. However, most side effects are temporary. It can often be difficult to distinguish the symptoms of your illness from side effects.
Get in touch with your doctor immediately if you experience any of the following serious side effects:
Rare(may affect up to 1 in 100 people):
Very rare(may affect up to 1 in 1,000 people):
Frequency not known(cannot be estimated from available data):
You may experience any of the side effects listed below. These possible side effects are generally of mild or moderate intensity and may disappear over time. However, if the side effect is severe or persistent, consult your doctor.
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Rare(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Frequency not known(cannot be estimated from available data):
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack or the box.The expiration date is the last day of the month indicated.
Store below 30°C. Store in the original packaging to protect it from moisture.
“Medicines should not be disposed of through drains or in the trash. Dispose of the containers and medicines you no longer need at
Composition of Ziprasidona Viatris
The active ingredient is ziprasidone.
Each hard capsule contains ziprasidone hydrochloride monohydrate equivalent to 80 mg of ziprasidone.
The other components are:
The capsule content is potassium polacrilex, lactose monohydrate, povidone, magnesium stearate.
The capsule coating contains Brilliant Blue FCF (E-133), titanium dioxide (E-171), and gelatin.
The printing components are shellac, propylene glycol, iron oxide black (E-172), and potassium hydroxide.
Appearance of the product and contents of the package
Hard gelatin capsule formed by an opaque blue-colored size 1 capsule (19.1 mm to 19.7 mm) and an opaque white body, with the imprint in the axial direction “MYLAN” above “ZE80”, in black ink on the capsule and body.
Ziprasidona Viatris is available in blisters of 10, 14, 20, 28, 30, 50, 56, 60, 90, 100, and 180 hard capsules and in perforated single-dose blisters containing 14 and 56 hard capsules.
Only some package sizes may be marketed.
Marketing Authorization Holder and Responsible Manufacturer
Marketing Authorization Holder
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Responsible Manufacturer
Mylan Germany GmbH
Benzstrasse 1
61352 Bad Homburg
Germany
or
Mylan Hungary Kft
H-2900 Komárom
Mylan utca 1
Hungary
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.
C/ General Aranaz, 86
28027 - Madrid
Spain
This medicine is authorized in the Member States of the European Economic Area with the following names:
GermanyZiprasidon Mylan 80 mg Hartkapseln
SlovakiaZiprasidon Mylan
SpainZiprasidona Viatris
PortugalZiprasidona Mylan
Czech RepublicZiprasidon Aurobindo
Last review date of this leaflet:March 2020
More detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) https://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.